Sanofi's (SNY.US) drug failed to meet the primary endpoint in two relapsing multiple sclerosis trials.

Market VisionMonday, Sep 2, 2024 8:40 am ET

1min read

Sanofi's (SNY.US) MS candidate tolebrutinib failed to meet the primary endpoints in two studies. In the GEMINI1 and GEMINI2 studies, the drug did not significantly reduce the annualized relapse rate compared to Sanofi's Aubagio (a purine synthesis inhibitor used to treat relapsing MS).

However, tolebrutinib did meet the primary endpoint in the HERCULES Phase 3 study, delaying the onset of confirmed disability progression in non-relapsing secondary progressive MS, which currently has no approved treatment.

Sanofi has been seeking multiple opportunities in the MS field as its popular MS drug Aubagio faces generic competition.

Sanofi is still testing tolebrutinib in the PERSEUS Phase 3 study to treat primary progressive MS and assess the time to onset of confirmed disability progression. Results are expected in 2025.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.